Vinorelbine LU vinorelbine (as tartrate) 30 mg soft capsules blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

vinorelbine tartrate, Quantity: 41.55 mg (Equivalent: vinorelbine, Qty 30 mg)

Available from:

Luminarie Pty Ltd

Pharmaceutical form:

Capsule, soft

Composition:

Excipient Ingredients: Gelatin; iron oxide red; partially dehydrated liquid sorbitol; titanium dioxide; macrogol 400; purified water; polysorbate 80

Administration route:

Oral

Units in package:

1 capsule

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Non-small cell lung cancer: Vinorelbine LU is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination. ,Breast cancer: Vinorelbine LU is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Product summary:

Visual Identification: oblong-shaped pink soft capsule; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered

Authorization date:

2023-02-14